Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension

Benjamin Woolf; James A Perry; Charles C Hong; Martin R Wilkins; Mark Toshner; Dipender Gill; Stephen Burgess; Christopher J Rhodes

doi:10.1183/13993003.02031-2023

Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension

Eur Respir J. 2024 Apr 4;63(4):2302031. doi: 10.1183/13993003.02031-2023. Print 2024 Apr.

Authors

Benjamin Woolf^{1

2

3}, James A Perry⁴, Charles C Hong⁵, Martin R Wilkins⁶, Mark Toshner⁷, Dipender Gill⁸, Stephen Burgess^{3

9}, Christopher J Rhodes⁶

Affiliations

¹ The MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK benjamin.woolf@bristol.ac.uk.
² School of Psychological Science, University of Bristol, Bristol, UK.
³ The MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
⁴ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
⁵ Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI, USA.
⁶ National Heart and Lung Institute, Imperial College London, London, UK.
⁷ Department of Medicine, University of Cambridge, Cambridge, UK.
⁸ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
⁹ British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Abstract

In the most comprehensive analysis to date, this study failed to detect an association of genetically predicted CRP-weighted IL-6 signalling or CRP-weighted IL-6R signalling with PAH risk using all available PAH GWAS data https://bit.ly/3T5h5uj

Publication types

Letter

MeSH terms

Biological Specimen Banks
Familial Primary Pulmonary Hypertension
Genome-Wide Association Study
Humans
Interleukin-6* / genetics
Polymorphism, Single Nucleotide
Pulmonary Arterial Hypertension*
Risk Factors

Substances

Interleukin-6

Grants and funding

225790/WT_/Wellcome Trust/United Kingdom